PE20030601A1 - Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados - Google Patents

Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados

Info

Publication number
PE20030601A1
PE20030601A1 PE2002000944A PE2002000944A PE20030601A1 PE 20030601 A1 PE20030601 A1 PE 20030601A1 PE 2002000944 A PE2002000944 A PE 2002000944A PE 2002000944 A PE2002000944 A PE 2002000944A PE 20030601 A1 PE20030601 A1 PE 20030601A1
Authority
PE
Peru
Prior art keywords
alkyl
diabetes
treatment
related disorders
naphthyridine
Prior art date
Application number
PE2002000944A
Other languages
English (en)
Inventor
William H Bullock
David E Gunn
Tindy Li
Sidney X Liang
Qingjie Liu
Jill E Wood
Steven R Magnuson
Eric S Mull
Ning Qi
Yamin Wang
Donglei Liu
Original Assignee
Bayer Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Corp filed Critical Bayer Corp
Publication of PE20030601A1 publication Critical patent/PE20030601A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/10—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH
    • A61P5/12—Drugs for disorders of the endocrine system of the posterior pituitary hormones, e.g. oxytocin, ADH for decreasing, blocking or antagonising the activity of the posterior pituitary hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Saccharide Compounds (AREA)

Abstract

SE REFIERE A DERIVADOS DE 1,8-NAFTIRIDINA DE FORMULA I DONDE R1 ES ALQUILO C1-C8, ALQUENILO C2-C8, ALQUINILO C2-C8; R1 ES ARILO C6-C10, HETEROARILO C2-C9 Y 1-4 HETEROATOMOS; R2 ES NR15R16, S(O)0-2R17, OR17; R15 ES H, ALQUILO C1-C6, ALQUENILO C2-C6, ALQUINILO C2-C6, CICLOALQUILO C3-C8, ENTRE OTROS; R16 ES ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS; R17 ES ALQUILO C1-C8, ALQUENILO C2-C8, ENTRE OTROS; R3 ES ARILO C6-C10, HETEROARILO C2-C9 DE 1-4 HETEROATOMOS; R4 ES =O, =S, OR21; R1 ES H, ALQUILO C1-C8, ENTRE OTROS; R5 Y R6 SON CICLOALQUILO C3-C8, CICLOALQUENILO C4-C8, ARILO C6-C10, ENTRE OTROS; R7 ES CICLOALQUILO C3-C8, CICLOALQUENILO C4-C8, ENTRE OTROS. SON COMPUESTOS PREFERIDOS 2-ANILINO-5-METIL-1-FENIL-1,8-NAFTIRIDIN-4(1H)-ONA, 5-METIL-7-MORFOLIN-4-IL-1-FENIL-2-FENILAMINO-1H-[1,8]-NAFTIRIDIN-4-ONA, ENTRE OTROS. SE REFIERE TAMBIEN A UNA COMPOSICION FARMACEUTICA. LOS COMPUESTOS MENCIONADOS SON UTILES PARA EL TRATAMIENTO DE DIABETES Y TRASTORNOS RELACIONADOS
PE2002000944A 2001-09-26 2002-09-25 Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados PE20030601A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US32451101P 2001-09-26 2001-09-26

Publications (1)

Publication Number Publication Date
PE20030601A1 true PE20030601A1 (es) 2003-09-07

Family

ID=23263913

Family Applications (2)

Application Number Title Priority Date Filing Date
PE2002000943A PE20030549A1 (es) 2001-09-26 2002-09-25 Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
PE2002000944A PE20030601A1 (es) 2001-09-26 2002-09-25 Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados

Family Applications Before (1)

Application Number Title Priority Date Filing Date
PE2002000943A PE20030549A1 (es) 2001-09-26 2002-09-25 Derivados de 1,6-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados

Country Status (24)

Country Link
US (5) US6677352B1 (es)
EP (2) EP1432710A1 (es)
JP (2) JP2005504808A (es)
KR (2) KR20040041177A (es)
CN (2) CN1578781A (es)
AR (2) AR037504A1 (es)
BR (2) BR0212864A (es)
CA (2) CA2461132A1 (es)
CO (2) CO5560611A2 (es)
EC (2) ECSP045084A (es)
GT (2) GT200200194A (es)
HN (1) HN2002000275A (es)
HR (2) HRP20040309A2 (es)
HU (2) HUP0402310A2 (es)
IL (2) IL160708A0 (es)
MA (2) MA26344A1 (es)
MX (2) MXPA04002035A (es)
NO (2) NO20041560L (es)
PE (2) PE20030549A1 (es)
PL (2) PL369531A1 (es)
RU (2) RU2004112787A (es)
UY (2) UY27456A1 (es)
WO (2) WO2003027113A1 (es)
ZA (2) ZA200403063B (es)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUP0402310A2 (hu) * 2001-09-26 2005-02-28 Bayer Pharmaceuticals Corporation 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények
WO2003061651A1 (en) * 2002-01-22 2003-07-31 The Regents Of The University Of California Non-steroidal ligands for the glucocorticoid receptor, compositions and uses thereof
WO2005018567A2 (en) * 2003-08-22 2005-03-03 Bayer Pharmaceuticals Corporation Compounds and compositions for the treatment of diabetes and diabetes-related disorders
US7728141B2 (en) * 2003-11-04 2010-06-01 Merck Sharp & Dohme Corp. Substituted naphthyridinone derivatives
US20080125403A1 (en) 2004-04-02 2008-05-29 Merck & Co., Inc. Method of Treating Men with Metabolic and Anthropometric Disorders
JP2008508243A (ja) * 2004-07-30 2008-03-21 パルメド・ソシエテ・アノニム アミノキノリンをｑとし、抗生物質残基をａとする混成分子ｑａ、その合成及び抗菌剤としての使用
FR2874922A1 (fr) * 2004-07-30 2006-03-10 Palumed Sa Molecules hybrides qa ou q est une aminoquinoleine et a est un residu antibiotique, leur synthese et leurs utilisations en tant qu'agent antibacterien
EP2275095A3 (en) 2005-08-26 2011-08-17 Braincells, Inc. Neurogenesis by muscarinic receptor modulation
EP2258359A3 (en) 2005-08-26 2011-04-06 Braincells, Inc. Neurogenesis by muscarinic receptor modulation with sabcomelin
CA2620275A1 (en) * 2005-08-26 2007-03-01 Thomas S. Scanlan Non-steroidal antiandrogens
US7985756B2 (en) 2005-10-21 2011-07-26 Braincells Inc. Modulation of neurogenesis by PDE inhibition
EP1942879A1 (en) 2005-10-31 2008-07-16 Braincells, Inc. Gaba receptor mediated modulation of neurogenesis
US20100216734A1 (en) 2006-03-08 2010-08-26 Braincells, Inc. Modulation of neurogenesis by nootropic agents
MX2008014320A (es) 2006-05-09 2009-03-25 Braincells Inc Neurogenesis mediada por el receptor de 5-hidroxitriptamina.
JP2009536669A (ja) 2006-05-09 2009-10-15 ブレインセルス，インコーポレイティド アンジオテンシン調節による神経新生
JP2010502722A (ja) 2006-09-08 2010-01-28 ブレインセルス，インコーポレイティド ４−アシルアミノピリジン誘導体を含む組み合わせ
US20100184806A1 (en) 2006-09-19 2010-07-22 Braincells, Inc. Modulation of neurogenesis by ppar agents
WO2008074068A1 (en) * 2006-12-20 2008-06-26 Prana Biotechnology Limited Substituted quinoline derivatives as antiamyloidogeneic agents
EP2150544B1 (en) * 2007-03-19 2016-01-13 Takeda Pharmaceutical Company Limited Mapk/erk kinase inhibitors
US10017827B2 (en) 2007-04-04 2018-07-10 Nidera S.A. Herbicide-resistant sunflower plants with multiple herbicide resistant alleles of AHASL1 and methods of use
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
WO2008151257A2 (en) 2007-06-04 2008-12-11 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009256157B2 (en) 2008-06-04 2014-12-18 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
MX2011004258A (es) 2008-10-22 2011-06-01 Merck Sharp & Dohme Derivados de bencimidazol ciclicos novedosos utiles como agentes anti-diabeticos.
EP2362731B1 (en) 2008-10-31 2016-04-06 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US20100216805A1 (en) 2009-02-25 2010-08-26 Braincells, Inc. Modulation of neurogenesis using d-cycloserine combinations
ME01838B (me) 2009-06-29 2014-12-20 Lncyte Holdings Corp Pirimidinoni kao inhibitori pi3k
WO2011075643A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted heteroaryl fused derivatives as pi3k inhibitors
WO2011075630A1 (en) * 2009-12-18 2011-06-23 Incyte Corporation Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors
CA2786314A1 (en) 2010-02-25 2011-09-01 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
AR081823A1 (es) 2010-04-14 2012-10-24 Incyte Corp DERIVADOS FUSIONADOS COMO INHIBIDORES DE PI3Kd
US9062055B2 (en) 2010-06-21 2015-06-23 Incyte Corporation Fused pyrrole derivatives as PI3K inhibitors
WO2012027331A1 (en) 2010-08-27 2012-03-01 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
AR084366A1 (es) 2010-12-20 2013-05-08 Incyte Corp N-(1-(fenil sustituido)etil)-9h-purin-6-aminas como inhibidores de pi3k
BR122021002201A8 (pt) 2011-02-25 2023-04-11 Merck Sharp & Dohme Composto, composição, uso de um composto, e, método de tratamento de um distúrbio, condição ou doença
US9108984B2 (en) 2011-03-14 2015-08-18 Incyte Corporation Substituted diamino-pyrimidine and diamino-pyridine derivatives as PI3K inhibitors
US9126948B2 (en) 2011-03-25 2015-09-08 Incyte Holdings Corporation Pyrimidine-4,6-diamine derivatives as PI3K inhibitors
WO2013007676A1 (en) * 2011-07-12 2013-01-17 F. Hoffmann-La Roche Ag Aminomethyl quinolone compounds
EA033646B1 (ru) 2011-09-02 2019-11-13 Incyte Holdings Corp Гетероциклиламины как ингибиторы pi3k
EP2804603A1 (en) 2012-01-10 2014-11-26 President and Fellows of Harvard College Beta-cell replication promoting compounds and methods of their use
AR090548A1 (es) 2012-04-02 2014-11-19 Incyte Corp Azaheterociclobencilaminas biciclicas como inhibidores de pi3k
KR20150036245A (ko) 2012-08-02 2015-04-07 머크 샤프 앤드 돔 코포레이션 항당뇨병 트리시클릭 화합물
MX2015010935A (es) 2013-02-22 2015-10-29 Merck Sharp & Dohme Compuestos biciclicos antidiabeticos.
CN103183676B (zh) * 2013-03-12 2015-04-08 中国医学科学院医药生物技术研究所 一组1-取代-1,8萘啶甲酰胺衍生物及制备和应用
JP2016512507A (ja) 2013-03-13 2016-04-28 ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ ヒト免疫不全ウイルス複製の阻害剤
US9650375B2 (en) 2013-03-14 2017-05-16 Merck Sharp & Dohme Corp. Indole derivatives useful as anti-diabetic agents
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
WO2014197720A2 (en) 2013-06-05 2014-12-11 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase c, method of making and using same
JO3442B1 (ar) * 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US9409922B2 (en) 2014-02-18 2016-08-09 Bristol-Myers Squibb Company Imidazopyridine macrocycles as inhibitors of human immunodeficiency virus replication
WO2015191677A1 (en) 2014-06-11 2015-12-17 Incyte Corporation Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors
WO2016138363A1 (en) 2015-02-27 2016-09-01 Incyte Corporation Salts of pi3k inhibitor and processes for their preparation
US9732097B2 (en) 2015-05-11 2017-08-15 Incyte Corporation Process for the synthesis of a phosphoinositide 3-kinase inhibitor
US9988401B2 (en) 2015-05-11 2018-06-05 Incyte Corporation Crystalline forms of a PI3K inhibitor
CN108026113A (zh) 2015-08-10 2018-05-11 Viiv保健英国第五有限公司 作为人免疫缺陷病毒复制的抑制剂的咪唑并吡啶大环类化合物
JOP20190086A1 (ar) * 2016-10-21 2019-04-18 Novartis Ag مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب
EA038455B1 (ru) * 2016-10-26 2021-08-31 Новартис Аг Новые производные нафтиридинона и их применение в лечении аритмии
EP3551176A4 (en) 2016-12-06 2020-06-24 Merck Sharp & Dohme Corp. ANTIDIABETIC HETEROCYCLIC COMPOUNDS
US10968232B2 (en) 2016-12-20 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
CN110981869A (zh) * 2019-12-10 2020-04-10 天津科技大学 一种1,8-双氮杂色酮的合成方法及其在抗糖尿病药物中的应用
KR102660894B1 (ko) * 2021-09-17 2024-04-26 기초과학연구원 피리미딘-2-아민 화합물의 제조방법

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US990774A (en) * 1910-03-15 1911-04-25 John W P Reid Convertible core for building-blocks.
DE2808070A1 (de) 1978-02-24 1979-08-30 Bayer Ag Verfahren zur herstellung von 4-pyridon-3-carbonsaeuren und/oder deren derivaten
US4616019A (en) 1984-01-26 1986-10-07 Abbott Laboratories Naphthyridine antibacterial compounds
DE3508816A1 (de) 1985-01-10 1986-07-10 Bayer Ag, 5090 Leverkusen 6,7-disubstituierte 1-cyclopropyl-1,4-dihydro-4-oxo-1,8-naphtyridin-3-carbonsaeuren
US4988705A (en) * 1985-06-13 1991-01-29 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US5126352A (en) 1985-06-13 1992-06-30 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4810708A (en) 1986-05-15 1989-03-07 Schering Corporation Polycyclic quinoline, naphthyridine and pyrazinopyridine derivatives
US4767762A (en) * 1985-12-23 1988-08-30 Abbott Laboratories Tricyclic quinoline and naphthyride antibacterials
DE3804990A1 (de) 1988-02-18 1989-08-31 Basf Ag Herbizid wirksame, heterocyclisch substituierte sulfonamide
JPH02124871A (ja) 1988-07-27 1990-05-14 Dainippon Pharmaceut Co Ltd １位が置換された複素環式カルボン酸アミド誘導体
CA2001203C (en) 1988-10-24 2001-02-13 Thomas P. Demuth, Jr. Novel antimicrobial dithiocarbamoyl quinolones
CA2012681A1 (en) 1989-03-31 1990-09-30 Masayasu Okuhira Quinolone derivatives, preparation processes thereof, and antibacterial agents containing the same
JP2787713B2 (ja) * 1989-07-28 1998-08-20 富山化学工業株式会社 新規なイソチアゾローナフチリジンおよびイソチアゾローキノリン誘導体並びにそれらの塩
JP3012684B2 (ja) * 1989-12-08 2000-02-28 大日本製薬株式会社 チエノキノリン誘導体、チエノナフチリジン誘導体およびそれらの塩
GB9013615D0 (en) * 1990-06-19 1990-08-08 Wellcome Found Pharmaceutical compounds
GB9023289D0 (en) 1990-10-25 1990-12-05 Ici Plc Herbicides
IL101860A0 (en) 1991-05-31 1992-12-30 Ici Plc Heterocyclic derivatives
KR950704314A (ko) 1992-12-01 1995-11-17 가와노 다케히코 1,8-나프티리딘-2-온 유도체 및 그 사용 방법(1,8-naphthyridin-2-one derivative and use thereof)
DE4303657A1 (de) 1993-02-09 1994-08-11 Bayer Ag Neue Chinolon- und Naphthyridoncarbonsäurederivate
EP0787726B1 (en) 1994-06-14 2001-11-28 Dainippon Pharmaceutical Co., Ltd. Novel compound, process for producing the same, and antitumor agent
JP3242792B2 (ja) * 1994-08-05 2001-12-25 日本臓器製薬株式会社 ナフチリジニウム誘導体
WO1996006843A1 (fr) 1994-08-29 1996-03-07 Yamanouchi Pharmaceutical Co., Ltd. Nouveau derive de naphtyridine et composition medicinale a base de ce derive
US6331555B1 (en) * 1995-06-01 2001-12-18 University Of California Treatment of platelet derived growth factor related disorders such as cancers
DE69628019T2 (de) 1995-08-02 2004-01-22 Darwin Discovery Ltd., Slough Chinolone und deren therapeutische verwendung
JP4323574B2 (ja) 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
BR9710808A (pt) 1996-08-06 1999-08-17 Pfizer Derivados biciclicos 6,6 ou 6,7 contendo pirito ou pirimido substitu¡dos
US6274592B1 (en) * 1997-02-04 2001-08-14 Senju Pharmaceutical Co., Ltd. Method for stabilizing arylcarboxylic acid, stabilizer thereof and aqueous solution containing stabilized arylcarboxylic acid
US5994367A (en) * 1997-03-07 1999-11-30 The University Of North Carolina At Chapel Hill Method for treating tumors using 2-aryl-naphthyridin-4-ones
KR20000068711A (ko) 1997-08-06 2000-11-25 도리이 신이치로 Ⅳ형 포스포디에스테라제 억제제로서의 1-아릴-1,8-나프틸리딘-4-온 유도체
GB9720052D0 (en) 1997-09-19 1997-11-19 Smithkline Beecham Plc Novel compounds
HUP0002353A3 (en) 1998-01-29 2001-11-28 Daiichi Asubio Pharma Co Ltd 1-cycloalkyl-1,8-naphthyridin-4-one derivatives with phoshodiesterase iv inhibitory activity and pharmaceutical compositions containing them
KR100286874B1 (ko) * 1998-03-04 2001-04-16 성재갑 보호된 4-아미노메틸-피롤리딘-3-온의 제조방법
US6288234B1 (en) 1998-06-08 2001-09-11 Advanced Medicine, Inc. Multibinding inhibitors of microsomal triglyceride transferase protein
AU4694999A (en) * 1998-08-06 2000-02-28 Warner-Lambert Company Use of thiazolidinedione derivatives for the treatment or prevention of cataracts
US6423721B1 (en) * 1998-09-10 2002-07-23 Schering Corporation Methods and compositions for treating sinusitis, otitis media and other related disorders using antihistamines
JP4681734B2 (ja) 1998-09-18 2011-05-11 千寿製薬株式会社 ピリドンカルボン酸の可溶化方法、その可溶化剤、ピリドンカルボン酸含有水溶液剤およびその製造方法
WO2000071524A1 (en) 1999-05-19 2000-11-30 Smithkline Beecham Plc 2-nh-pyridones and pyrimidones as mrs inhibitors
JP2003531205A (ja) 2000-04-24 2003-10-21 ブリストル−マイヤーズ スクイブ カンパニー Ｉｍｐｄｈ酵素の阻害剤である複素環化合物
HUP0402310A2 (hu) * 2001-09-26 2005-02-28 Bayer Pharmaceuticals Corporation 1,6-Naftiridin-származékok mint antidiabetikumok és ezeket tartalmazó gyógyszerkészítmények

Also Published As

Publication number Publication date
MA27079A1 (fr) 2004-12-20
JP2005504807A (ja) 2005-02-17
MA26344A1 (fr) 2004-10-01
KR20040041177A (ko) 2004-05-14
NO20041560L (no) 2004-05-11
US6900205B2 (en) 2005-05-31
US20040209866A1 (en) 2004-10-21
RU2004112787A (ru) 2005-10-10
ECSP045081A (es) 2004-06-28
GT200200191A (es) 2003-05-23
US6964971B2 (en) 2005-11-15
CN1578781A (zh) 2005-02-09
US20040014751A1 (en) 2004-01-22
HN2002000275A (es) 2005-02-22
US7109196B2 (en) 2006-09-19
BR0212829A (pt) 2004-08-03
RU2004112771A (ru) 2005-10-10
CA2463039A1 (en) 2003-04-03
HRP20040317A2 (en) 2006-06-30
US6677352B1 (en) 2004-01-13
WO2003027113A1 (en) 2003-04-03
NO20041567L (no) 2004-05-11
AR037503A1 (es) 2004-11-17
PL369531A1 (en) 2005-05-02
CO5560542A2 (es) 2005-09-30
ECSP045084A (es) 2004-06-28
MXPA04002035A (es) 2004-06-07
UY27456A1 (es) 2003-04-30
CN1578780A (zh) 2005-02-09
WO2003027112A1 (en) 2003-04-03
CA2461132A1 (en) 2003-04-03
PE20030549A1 (es) 2003-08-18
HUP0402310A2 (hu) 2005-02-28
PL369567A1 (en) 2005-05-02
GT200200194A (es) 2003-07-03
HRP20040309A2 (en) 2006-05-31
CO5560611A2 (es) 2005-09-30
MXPA04002136A (es) 2005-03-07
US20060189609A1 (en) 2006-08-24
IL160708A0 (en) 2004-08-31
KR20040041178A (ko) 2004-05-14
EP1432711A1 (en) 2004-06-30
HUP0401889A2 (hu) 2005-01-28
AR037504A1 (es) 2004-11-17
JP2005504808A (ja) 2005-02-17
ZA200403063B (en) 2005-04-22
IL160707A0 (en) 2004-08-31
US20040157875A1 (en) 2004-08-12
EP1432710A1 (en) 2004-06-30
UY27457A1 (es) 2003-04-30
BR0212864A (pt) 2004-08-17
ZA200403064B (en) 2005-06-29

Similar Documents

Publication Publication Date Title
PE20030601A1 (es) Derivados de 1,8-naftiridina y su uso para el tratamiento de la diabetes y transtornos relacionados
CR8505A (es) Derivados de (3-oxo-3,4-dihidroquinoxalin-2-il-amino)-benzamida y compuesto relacionado, como inhibidores de glucogeno fosforilasa para el tratamiento de la diabetes y obesidad
CO5680479A2 (es) Derivados de pirimidilsulfonamida como moduladores del receptor de quimiocina, sus composiciones y proceso de obtencion
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
PE20070212A1 (es) Heterociclos de 1,4-dihidropiridina-condensados, procesos para preparar los mismos, uso y composiciones que los contienen
PE20040155A1 (es) Derivados aminoinazoles, procedimiento de preparacion e intermedios de este procedimiento a titulo de medicamentos y composiciones farmaceuticas que los contienen
AR055878A1 (es) Derivados de ciclopropanocarboxamida
PA8575401A1 (es) Derivados de heteroarilamida benzocondensada de tienopiridinas utiles como agentes terapeuticos, composiciones farmaceuticas que incluyen a los mismos y metrodos para su uso
AR042706A1 (es) Compuestos (2-carboxamido)(3-amino) tiofenos y su uso para el tratamiento del cancer
ATE487715T1 (de) Triazolderivate als modulatoren von dopamin-d3- rezeptoren
BR122012009489B8 (pt) processo para produzir 2-etóxi-1-{[2’-(5-oxo-4,5-diidro-1,2,4-oxadiazol-3-il)bifenil-4-il]metil}-1h-benzimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metila ou um sal do mesmo, composição farmacéutica, e, uso
BRPI0608732A2 (pt) composto ou um sal, hidrato, solvato, complexo ou pró-droga farmaceuticamente aceitável do mesmo, sal de um composto, processo para a preparação de um composto, uso de um composto, composição farmacêutica, e, produto
PE20061303A1 (es) Composicion farmaceutica que comprende oxaprozina
CO5550451A2 (es) Derivados de 3-(sulfonamidoetil)-indol para uso como mimeti- cos de glucocorticoides en el tratamiento de enfermedades inflamatorias, alergicas y proliferativas
PE20020589A1 (es) 5-espiropirimidin-2,4,6-triona como inhibidores de metaloproteinasas
AR037901A1 (es) Beta-amino-alfa-cianoacrilatos
SE0301446D0 (sv) New Compounds
DE602006019221D1 (de) Von dopamin-d3-rezeptoren
AR056574A1 (es) Derivados de pirazol, composiciones que contienen dichos compuestos y procedimientos de uso
PE20050420A1 (es) Fenacilo 2-hidroxi-3-diaminoalcanos
DE602006004882D1 (de) Azabicycloä3.1.0ühexylphenylderivate als modulatoren von dopamin-d3-rezeptoren
RU2007128080A (ru) Производные пирролидиния в качестве мускариновых рецепторов мз
ATE322912T1 (de) Radiomarkierte pyrimidinnukleoside zur diagnose von gewebe-reproduzierender aktivität
RU2010115337A (ru) Трициклические гетероциклические производные
AR036176A1 (es) Un derivado de fenil-acetamido-tiazol, un procedimiento para su preparacion, una composicion farmaceutica que lo comprende, un producto o kit que los comprende, y un metodo que utiliza dicho derivado

Legal Events

Date Code Title Description
FC Refusal